Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).

11 Jan 2010

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

Scientists at deCODE genetics today report the discovery of seven novel and common single-letter variations in the sequence of the human genome (SNPs) that are involved in modulating the electrical impulses that govern the working of the heart.

11 Jan 2010

European Society of Cardiology warns public about risk factors involved in obesity, diabetes and hypertension

Following the sudden death yesterday of the former French government minister Philippe Séguin, who suffered a fatal heart attack, aged 66, the European Society of Cardiology is warning the public of the dangers of leaving risk factors such as hyperlipidemia, hypertension or diabetes untreated. Other major risk factors for coronary artery disease are smoking or being overweight.

9 Jan 2010

New iPhone application offers videos from a wide range of health topics

icyou today announced the launch of its iPhone app. Available for free on Apple's iPhone App Store, the application gives users convenient access to important health information when and where they choose. icyou Health Video for iPhone is available as a free download from Apple's App Store on iPhone and iPod touch or at www.itunes.com/appstore/.

9 Jan 2010

Amira Pharmaceuticals achieves another development milestone in its FLAP program

Amira Pharmaceuticals, Inc. announced today that it has achieved another development milestone in its FLAP program, which is partnered with GlaxoSmithKline. This milestone is related to the successful development of a solid dose formulation, which is critical for future development and commercialization activities.

8 Jan 2010

Young men with HIV infection have coronary atherosclerotic plaques: MGH study

A Massachusetts General Hospital (MGH) study has found that relatively young men with longstanding HIV infection and minimal cardiac risk factors had significantly more coronary atherosclerotic plaques - some involving serious arterial blockage - than did uninfected men with similar cardiovascular risk.

8 Jan 2010

Genzyme enters into mutual cooperation agreement with Relational Investors

Genzyme Corporation and San-Diego based institutional investor Relational Investors LLC announced today that they have entered into a mutual cooperation agreement. Relational, a $6 billion private investment fund, began investing in Genzyme shares in late 2008 and currently owns approximately 4 percent of the company’s common stock.

8 Jan 2010

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata’s lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets.

8 Jan 2010

Survivors of pediatric cancer at greater risk for cardiovascular disease

Survivors of pediatric cancer are at greater risk for high cholesterol, diabetes and high blood pressure, all of which predispose them to heart disease. These risk factors for heart disease are being found at an earlier age than in the general population, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Jan 2010

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.

6 Jan 2010

Animal experiments show old antidepressant may reverse heart failure

A team of Johns Hopkins and other researchers have found in animal experiments that an antidepressant developed over 40 years ago can blunt and even reverse the muscle enlargement and weakened pumping function associated with heart failure.

6 Jan 2010

Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.

Bioheart, Inc. announced today that the company has signed distribution agreements with Restoration Medical, McRay Medical, Alamo Scientific and Morey Medical. These distributors will assist Bioheart with introducing its Home Heart Failure Monitoring Systems to physicians and hospitals throughout the United States.

6 Jan 2010

NewCardio announces two encouraging validation studies related to CardioBip

NewCardio, Inc., a cardiac diagnostic technology provider, announced today two encouraging validation studies related to CardioBip(TM), a hand-held patient-activated device for recording and wireless transmission of reconstructed 12-lead ECGs.

6 Jan 2010

Vitamin D deficiency may contribute to higher risk of death among African-Americans compared to whites

Vitamin D deficiency may contribute to a higher number of heart and stroke-related deaths among black Americans compared to whites, according to a University of Rochester Medical Center study.

6 Jan 2010

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

Formatech selects ViroMed’s VM206 for Fillanthropy Program

Today, Formatech has selected the next candidate for its Fillanthropy Program: ViroMed’s VM206 therapeutic cancer vaccine. Under the Fillanthropy Program, Formatech will donate the services required to aseptically fill and finish one lot of the vaccine to support ViroMed’s upcoming clinical trials.

5 Jan 2010

NQF endorses 70 measures to improve gathering of clinical electronic data

As an incremental step toward wider use of electronic data platforms to measure, report, and improve quality, the National Quality Forum (NQF) has endorsed 70 measures that combine data from two or more common electronic sources such as administrative claims, pharmacy and laboratory systems, and registries.

5 Jan 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

European Society of Cardiology warns public about risk factors involved in obesity, diabetes and hypertension

New iPhone application offers videos from a wide range of health topics

Amira Pharmaceuticals achieves another development milestone in its FLAP program

Young men with HIV infection have coronary atherosclerotic plaques: MGH study

Genzyme enters into mutual cooperation agreement with Relational Investors

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Survivors of pediatric cancer at greater risk for cardiovascular disease

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Animal experiments show old antidepressant may reverse heart failure

Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.

NewCardio announces two encouraging validation studies related to CardioBip

Vitamin D deficiency may contribute to higher risk of death among African-Americans compared to whites

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

Formatech selects ViroMed’s VM206 for Fillanthropy Program

NQF endorses 70 measures to improve gathering of clinical electronic data

Study examines relationship between parental vaccine refusal and risk of varicella infection in children

GIVI scientists discover anti-HIV molecule that enhances infection, reduces transmission

Headline results from first phase III study of Balaglitazone announced

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Newsletters you may be interested in